Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for PFE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 0.00
December 31, 2025 0.00
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 0.00
September 30, 2024 0.00
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 0.00
September 30, 2023 0.00
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 2.00B
December 31, 2021 0.00
September 30, 2021 0.00
June 30, 2021 0.00
March 31, 2021 0.00
December 31, 2020 0.00
September 30, 2020 0.00
June 30, 2020 0.00
Date Value
March 31, 2020 0.00
December 31, 2019 -91.00M
September 30, 2019 -55.00M
June 30, 2019 -122.00M
March 31, 2019 8.739B
December 31, 2018 4.87B
September 30, 2018 480.00M
June 30, 2018 -102.00M
March 31, 2018 5.691B
December 31, 2017 -206.00M
September 30, 2017 -245.00M
June 30, 2017 -98.00M
March 31, 2017 4.687B
December 31, 2016 -73.00M
September 30, 2016 -250.00M
June 30, 2016 -400.00M
March 31, 2016 4.704B
December 31, 2015 -98.00M
September 30, 2015 -24.00M
June 30, 2015 -187.00M
March 31, 2015 5.206B
December 31, 2014 901.00M
September 30, 2014 1.16B
June 30, 2014 1.165B
March 31, 2014 772.00M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Johnson & Johnson -138.00M
Eli Lilly & Co. 1.601B
Merck & Co., Inc. 714.00M
Bristol Myers Squibb Co. 0.00
Viatris, Inc. 149.30M